Testing effectiveness (Phase 2)Ended earlyNCT01422486What this trial is testingPhase 2 Study of Telintra® in Deletion 5q Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome (MDS) Telik 2
Testing effectiveness (Phase 2)Ended earlyNCT01222195What this trial is testingLenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)Who this might be right forLeukemia M.D. Anderson Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT01736683What this trial is testingStudy of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)Who this might be right forAnemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more Merck Sharp & Dohme LLC 74
Large-scale testing (Phase 3)Active Not RecruitingNCT02598661What this trial is testingStudy to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Who this might be right forMyelodysplastic Syndromes Geron Corporation 289
Testing effectiveness (Phase 2)Study completedNCT01015352What this trial is testingAzacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)Who this might be right forMyelodysplastic Syndromes Groupe Francophone des Myelodysplasies 98
Early research (Phase 1)Study completedNCT01062152What this trial is testingDose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Who this might be right forMyelodysplastic Syndrome Telik 19
Large-scale testing (Phase 3)Active Not RecruitingNCT00843882What this trial is testingLenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and AnemiaWho this might be right forAnemiaChronic Myelomonocytic LeukemiaDe Novo Myelodysplastic Syndrome+1 more National Cancer Institute (NCI) 247
Testing effectiveness (Phase 2)Study completedNCT02363491What this trial is testingA Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome Opsona Therapeutics Ltd. 96
Testing effectiveness (Phase 2)Ended earlyNCT01513317What this trial is testingA Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome Janssen Research & Development, LLC 76
Testing effectiveness (Phase 2)Ended earlyNCT00495547What this trial is testingSIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome PETHEMA Foundation 16
Testing effectiveness (Phase 2)Ended earlyNCT02240706What this trial is testingPhase I/II Trial to Investigate BI 836858 in Myelodysplastic SyndromesWho this might be right forMyelodysplastic Syndromes Boehringer Ingelheim 27
Testing effectiveness (Phase 2)Study completedNCT00700206What this trial is testingPhase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)Who this might be right forMyelodysplastic Syndrome (MDS) Telik 86
Testing effectiveness (Phase 2)Ended earlyNCT00699842What this trial is testingA Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) PatientsWho this might be right forMyelodysplastic SyndromeMDSLow to Intermediate-1 MDS+1 more Sidney Kimmel Cancer Center at Thomas Jefferson University 8
Testing effectiveness (Phase 2)Study completedNCT03337451What this trial is testingFollow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome Opsona Therapeutics Ltd. 14
Testing effectiveness (Phase 2)Ended earlyNCT01459159What this trial is testingStudy of (Telintra®) in Non-Del(5q) Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome (MDS) Telik 162
Testing effectiveness (Phase 2)WithdrawnNCT00446602What this trial is testingEvaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)Who this might be right forMyelodysplastic SyndromesAnemia Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Testing effectiveness (Phase 2)Study completedNCT01338337What this trial is testingStudy of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent AnaemiaWho this might be right forMyelodysplastic Syndrome (MDS) Asociación Andaluza de Hematología y Hemoterapia 40
Testing effectiveness (Phase 2)Study completedNCT00418665What this trial is testingA Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidWho this might be right forMyelodysplastic SyndromesThrombocytopenia Amgen 39
Testing effectiveness (Phase 2)Study completedNCT02335268What this trial is testingValidation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and ThrombocytopeniaWho this might be right forMyelodysplastic Syndromes Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 77
Early research (Phase 1)WithdrawnNCT02075034What this trial is testingThree Dosing Schedules of Oral Rigosertib in MDS PatientsWho this might be right forMyelodysplastic Syndrome Traws Pharma, Inc.